Roche reports positive data from Phase III influenza treatment trial

[cafead]

via Roche has announced positive topline data from the Phase III CENTERSTONE clinical trial of Xofluza (baloxavir marboxil), an antiviral treatment for influenza infection.

A single-dose oral treatment, Xofluza is designed to hinder viral replication by stopping the cap-dependent endonuclease protein, to lower the infectiousness and disease duration.

article source